Southern Medical University, Guangzhou, China.
The Sixth Medical Center of PLA General Hospital, Beijing, China.
Acta Cardiol. 2021 May;76(3):258-264. doi: 10.1080/00015385.2020.1720197. Epub 2020 Feb 14.
We investigated the risk of ischaemic stroke in patients with 1 another stroke risk factor (i.e. CHA2DS2-VASc score =1 [males] or 2 [females]) and the impact of different component risk factors.
Database were collected from two hospitals in the city of Hohhot in china. Among 3148 Nonvalvular AF patients not on antiplatelet or anticoagulant therapy, we evaluated males with a CHA2DS2-VASc score of 1 and females with a CHA2DS2-VASc score of 2. The clinical endpoint was the occurrence of ischaemic stroke.
Among 546 AF male patients with a CHA2DS2-VASc score of 1, there were 44 patients (8.06%) who experienced ischaemic stroke during follow-up (3.4 ± 2.1 years) with an annual stroke rate of 2.62%. The risk of ischaemic stroke ranged from 1.86%/year for patients with vascular diseases to 3.33%/year for those age 65-74 years of age. For the female patients with 653 AF, 54 (8.27%) experienced ischaemic stroke during follow-up (3.4 ± 2.1 years) , for an annual stroke rate of 2.76%. The risk of ischaemic stroke increased from 1.96%/year for patients with vascular diseases to 3.38%/year for those 65-74 years of age.
The risk of each factor is not equal in CHA2DS2-VASc score, with age 65-74 years associated with the highest stroke rate. Oral anticoagulation should be considered for AF patients with 1 another stroke risk factor given their high risk of ischaemic stroke.Article summary:The risk of each factor is not equal in CHA2DS2-VASc score.Atrial fibrillation is a risk factor of ischaemic stroke.Oral anticoagulation should be considered for AF patients with 1 another stroke risk factor given their high risk of ischaemic stroke.It is the retrospective nature of the study.We were not able to clearly confirm the cause of ischaemic stroke because it can be due to AF-related thromboembolism or atherosclerosis and thrombosis of the cerebral artery.
我们研究了另一个卒中风险因素（即 CHA2DS2-VASc 评分=1[男性]或 2[女性]）的患者发生缺血性卒中的风险，以及不同组分风险因素的影响。
本研究数据来自中国呼和浩特市的两家医院。在 3148 例未接受抗血小板或抗凝治疗的非瓣膜性房颤患者中，我们评估了 CHA2DS2-VASc 评分男性为 1 分和女性为 2 分的患者。临床终点为缺血性卒中的发生。
在 546 例 CHA2DS2-VASc 评分男性为 1 分的房颤患者中，有 44 例（8.06%）在随访期间（3.4±2.1 年）发生缺血性卒中，年卒中发生率为 2.62%。缺血性卒中风险范围从血管疾病患者的 1.86%/年到 65-74 岁患者的 3.33%/年。在 653 例 CHA2DS2-VASc 评分女性的房颤患者中，有 54 例（8.27%）在随访期间（3.4±2.1 年）发生缺血性卒中，年卒中发生率为 2.76%。缺血性卒中风险从血管疾病患者的 1.96%/年增加到 65-74 岁患者的 3.38%/年。
CHA2DS2-VASc 评分中每个因素的风险并不相等，65-74 岁年龄组与最高卒中发生率相关。鉴于缺血性卒中风险较高，对于具有另一个卒中风险因素的房颤患者，应考虑口服抗凝治疗。
CHA2DS2-VASc 评分中每个因素的风险并不相等。房颤是缺血性卒中的一个危险因素。鉴于缺血性卒中风险较高，对于具有另一个卒中风险因素的房颤患者，应考虑口服抗凝治疗。这是一项回顾性研究。我们无法明确确定缺血性卒中的原因，因为它可能是由于房颤相关的血栓栓塞或大脑动脉的动脉粥样硬化和血栓形成。
